Results 101 to 110 of about 924 (199)

Utilization of Heterocyclic Moieties for the Development of Anti-Microbial Agent to Combat Resistance [PDF]

Antimicrobial resistance (AMR) poses a significant global health challenge, threatening the effectiveness of current treatment regimens and necessitating the development of novel antimicrobial agents. This review provides a comprehensive overview of AMR,
Monika Barsagade
core   +1 more source

Resistance of Gram-Negative Bacteria to Eravacycline: A Systematic Review of Data from In Vitro Studies [PDF]

Introduction: Eravacycline is a new fluorocycline antibiotic with a broad spectrum of antimicrobial activity approved for the treatment of patients with complicated intra-abdominal infections.
Falagas, Matthew E., Filippou, Charalampos, Karageorgopoulos, Drosos E., Kontogiannis, Dimitrios S., Romanos, Laura T.   +4 more
core   +2 more sources

Successful Treatment with Sulbactam-Durlobactam for Severe Acute Pancreatitis Complicated by Extensively Drug-Resistant Acinetobacter baumannii Infection at Multiple Sites: A Case Report

Infection and Drug Resistance
Zhengmao Ge, Li Li, Longxin Wang, Dengke Liu, Yupeng Liu Department of Critical Care Medicine, The 967 Hospital, Joint Logistics Support Force of PLA, Dalian, 116021, People’s Republic of ChinaCorrespondence: Yupeng Liu, Department of Critical Care ...
Ge Z, Li L, Wang L, Liu D, Liu Y
doaj  

Carbapenem Resistance in Acinetobacter baumannii: Mechanisms, Therapeutics, and Innovations

Microorganisms
The global rise of carbapenem-resistant Acinetobacter baumannii (CRAB) strains poses a critical challenge to healthcare systems due to limited therapeutic options and high mortality rates, especially in intensive care settings.
Joyce de Souza, Helena Regina Salomé D’Espindula, Isabel de Farias Ribeiro, Geiziane Aparecida Gonçalves, Marcelo Pillonetto, Helisson Faoro   +5 more
doaj   +1 more source

Management of extensively drug-resistant Acinetobacter baumannii bacteremia with cefiderocol and sulbactam-durlobactam: a case report

ASM Case Reports
ABSTRACT Background Extensively drug-resistant (XDR) Acinetobacter baumannii presents an urgent threat to public health due to its significant morbidity and mortality, with limited evidence-based treatment options.
E. J. Kim, M. Snyder, K. Macaluso, A. Sonyey, F. Segovia, D. Finkel, D. Cennimo, E. L. Kim   +7 more
openaire   +2 more sources

β-Lactam/β-Lactamase Inhibitor Combinations in Sepsis-Associated Acute Kidney Injury and Renal Replacement Therapy

Antibiotics
Sepsis-associated acute kidney injury (SA-AKI) often requires renal replacement therapy (RRT), which markedly alters antimicrobial pharmacokinetics (PK) and pharmacodynamics (PD). Novel β-lactam/β-lactamase inhibitor (BL/BLI) combinations broaden options
Antonio Lacquaniti, Valentina Pistolesi, Antonella Smeriglio, Domenico Santoro, Cristina Iannetti, Giuseppe Lentini, Roberto Chimenz, Valeria Chirico, Domenico Trombetta, Santo Morabito, Paolo Monardo   +10 more
doaj   +1 more source

Multidrug resistance Acinetobacter species in ventilator associated pneumonia patients in MICU [PDF]

Background: Ventilator associated pneumonia (VAP) is defined as pneumonia that develops 48-72 hours after endotracheal intubation and is characterized by the presence of a new or progressive infiltrate, symptoms of systemic infection, respiratory ...
Harbade, Mangala S., Iravane, Jyoti A., Onkari, Amruta, Shaji, Eby P.   +3 more
core   +2 more sources

Sulbactam-durlobactam susceptibility among cefiderocol heteroresistant Acinetobacter

The ATTACK clinical trial for treatment of carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRAB) isolates determined treatment with sulbactam-durlobactam to be efficacious and safe.
Bikash Bogati, Tugba Ozturk, Sarah W Satola, David S Weiss   +3 more
openaire   +1 more source

Antibiotic Treatment of Carbapenem-Resistant Acinetobacter baumannii Infections in View of the Newly Developed β-Lactams: A Narrative Review of the Existing Evidence

Antibiotics
It is estimated that antimicrobial resistance (AMR) is responsible for nearly 5 million human deaths worldwide each year and will reach 10 million by 2050.
Francesca Serapide, Maurizio Guastalegname, Sara Palma Gullì, Rosaria Lionello, Andrea Bruni, Eugenio Garofalo, Federico Longhini, Enrico Maria Trecarichi, Alessandro Russo   +8 more
doaj   +1 more source

Susceptibilities of cefiderocol, meropenem-xeruborbactam, cefepime-taniborbactam, aztreonam-avibactam, and sulbactam-durlobactam against imipenem-non-susceptible Gram-negative bacilli in Taiwan

International Journal of Infectious Diseases
Objectives: To evaluate susceptibilities of novel antibiotics against imipenem-non-susceptible (INS) Escherichia coli (INS-EC), Klebsiella pneumoniae (INS-KP), Acinetobacter baumannii (INS-AB), Pseudomonas aeruginosa (INS-PA) in Taiwan, and the potential
Yan-Ru Wang, Yu-Lin Lee, Mei-Chen Tan, Pei-Jing Chen, I-Wen Huang, Jui-Fen Lai, Hui-Ying Wang, Yih-Ru Shiau, Shu-Chen Kuo, Ya-Sung Yang   +9 more
doaj   +1 more source